Biophytis SA
PAR:ALBPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biophytis SA
Selling, General & Administrative
Biophytis SA
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biophytis SA
PAR:ALBPS
|
Selling, General & Administrative
-€2m
|
CAGR 3-Years
25%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Selling, General & Administrative
-€74.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-12%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Selling, General & Administrative
-€9.7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-13%
|
|
|
Inventiva SA
PAR:IVA
|
Selling, General & Administrative
-€50.3m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Selling, General & Administrative
-$34.7m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
|
|
Abivax SA
PAR:ABVX
|
Selling, General & Administrative
-€72.9m
|
CAGR 3-Years
-113%
|
CAGR 5-Years
-67%
|
CAGR 10-Years
N/A
|
|
Biophytis SA
Glance View
Biophytis SA is a holding company. The company is headquartered in Paris, Ile-De-France and currently employs 24 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
See Also
What is Biophytis SA's Selling, General & Administrative?
Selling, General & Administrative
-2m
EUR
Based on the financial report for Jun 30, 2025, Biophytis SA's Selling, General & Administrative amounts to -2m EUR.
What is Biophytis SA's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-13%
Over the last year, the Selling, General & Administrative growth was -38%. The average annual Selling, General & Administrative growth rates for Biophytis SA have been 25% over the past three years , -13% over the past five years .
